GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CNBX Pharmaceuticals Inc (OTCPK:CNBX) » Definitions » Capex-to-Operating-Income

CNBX Pharmaceuticals (CNBX Pharmaceuticals) Capex-to-Operating-Income : 0.00 (As of Feb. 2024)


View and export this data going back to 2007. Start your Free Trial

What is CNBX Pharmaceuticals Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

CNBX Pharmaceuticals's Capital Expenditure for the three months ended in Feb. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Feb. 2024 was $-0.21 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


CNBX Pharmaceuticals Capex-to-Operating-Income Historical Data

The historical data trend for CNBX Pharmaceuticals's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CNBX Pharmaceuticals Capex-to-Operating-Income Chart

CNBX Pharmaceuticals Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CNBX Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CNBX Pharmaceuticals's Capex-to-Operating-Income

For the Biotechnology subindustry, CNBX Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CNBX Pharmaceuticals's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CNBX Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where CNBX Pharmaceuticals's Capex-to-Operating-Income falls into.



CNBX Pharmaceuticals Capex-to-Operating-Income Calculation

CNBX Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Aug. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -0.931
=N/A

CNBX Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Feb. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -0.206
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CNBX Pharmaceuticals  (OTCPK:CNBX) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


CNBX Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of CNBX Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


CNBX Pharmaceuticals (CNBX Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 Bethesda Metro Center, Suite 700, Bethesda, MD, USA, 20814
CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer research utilizing HTS technology and personalized bioinformatics tools. The company's main focus is the development of cannabinoid therapies and other technologies for the treatment of cancer, mainly cancers of the gastrointestinal tract, skin, breast, and prostate. The firm's main product is the RCC-33, an oral capsule for the treatment of colorectal cancer. The company tools include delivery systems, personalized medicine diagnostics, and therapies based on Cannabinoid compounds.
Executives
Cannabics Inc. 10 percent owner 108 WEST 13TH ST., WILMINGTON DE 19801
Thomas E Mills director, officer: President, CEO, CFO
North American Mining Corp 10 percent owner 6767 WEST TROPICANA AVENUE, SUITE 229, LAS VEGAS NV 89103
Lou Hilford director, officer: Vice-President, Secretary